-
Something wrong with this record ?
lncRNAs in Non-Malignant Tissue Have Prognostic Value in Colorectal Cancer
JA. Thiele, P. Hosek, E. Kralovcova, P. Ostasov, V. Liska, J. Bruha, O. Vycital, J. Rosendorf, A. Opattova, J. Horak, M. Kralickova, P. Vodicka, P. Pitule,
Language English Country Switzerland
Document type Journal Article
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
30205577
DOI
10.3390/ijms19092672
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Kaplan-Meier Estimate MeSH
- Colorectal Neoplasms diagnosis epidemiology genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Biomarkers, Tumor genetics MeSH
- Prognosis MeSH
- Proportional Hazards Models MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- Retrospective Studies MeSH
- RNA, Long Noncoding genetics MeSH
- Aged MeSH
- Up-Regulation MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
Although colorectal cancer (CRC) is the third most frequent cause of cancer related death in Europe, clinically relevant biomarkers for therapy guidance and prognosis are insufficiently reliable. Long non-coding RNAs (lncRNAs) are RNAs over 200 nucleotides long that are not translated into proteins but can influence biological processes. There is emerging evidence for their involvement in solid cancer as oncogenes, tumour suppressors or regulators of cell proliferation and metastasis development. The goal of this study was to evaluate the prognostic effect of selected lncRNAs in a retrospective study on CRC patients from the Czech Republic. We used a quantitative PCR approach to measure the expression in paired non-malignant and tumour tissue samples of CRC patients of nine lncRNAs previously shown to be involved in cancer progression-ANRIL, CCAT1, GAS5, linc-ROR, MALAT1, MIR155HG, PCAT1, SPRY4-IT1 and TUG1. Associations between expression and expression ratios and clinical characteristics and survival were assessed by using univariable Cox proportional hazards models, Kaplan-Meier estimations with the Gehan-Wilcoxon test, the Mann-Whitney U test, the Kruskal-Wallis test and Spearman's correlations. A comparison of expression in tumour tissue (TT) and non-malignant mucosa tissue (MT) showed significant upregulation of CCAT1 and linc-ROR in TT (p < 0.001 and p = 0.001, respectively) and downregulation of ANRIL, MIR155HG and MALAT1 (p = 0.001, p = 0.010, p = 0.001, respectively). Linc-ROR was significantly associated with the presence of synchronous metastases (p = 0.033). For individual tissue types, lower MIR155HG expression in TT was correlated with both shorter overall survival (p = 0.008) and shorter disease-free survival (p = 0.040). In MT, expression ratios of CCAT1/ANRIL and CCAT1/MIR155HG were associated with overall survival (p = 0.005 and p = 0.006, respectively). Our results revealed that changes in expression of lncRNAs between MT and TT hold potential to be used as prognostic biomarkers in CRC patients. Moreover, the ratios of CCAT1 to ANRIL and MIR155HG in MT also exhibit potential for prognosis assessment without tumour sampling. Our results also indicate that cancer progression is associated with detrimental system-wide changes in patient tissue, which might govern patient survival even after successful elimination of tumour or cancerous cells.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012387
- 003
- CZ-PrNML
- 005
- 20190405101230.0
- 007
- ta
- 008
- 190405s2018 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms19092672 $2 doi
- 035 __
- $a (PubMed)30205577
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Thiele, Jana-Aletta $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. Jana.A.Thiele@lfp.cuni.cz.
- 245 10
- $a lncRNAs in Non-Malignant Tissue Have Prognostic Value in Colorectal Cancer / $c JA. Thiele, P. Hosek, E. Kralovcova, P. Ostasov, V. Liska, J. Bruha, O. Vycital, J. Rosendorf, A. Opattova, J. Horak, M. Kralickova, P. Vodicka, P. Pitule,
- 520 9_
- $a Although colorectal cancer (CRC) is the third most frequent cause of cancer related death in Europe, clinically relevant biomarkers for therapy guidance and prognosis are insufficiently reliable. Long non-coding RNAs (lncRNAs) are RNAs over 200 nucleotides long that are not translated into proteins but can influence biological processes. There is emerging evidence for their involvement in solid cancer as oncogenes, tumour suppressors or regulators of cell proliferation and metastasis development. The goal of this study was to evaluate the prognostic effect of selected lncRNAs in a retrospective study on CRC patients from the Czech Republic. We used a quantitative PCR approach to measure the expression in paired non-malignant and tumour tissue samples of CRC patients of nine lncRNAs previously shown to be involved in cancer progression-ANRIL, CCAT1, GAS5, linc-ROR, MALAT1, MIR155HG, PCAT1, SPRY4-IT1 and TUG1. Associations between expression and expression ratios and clinical characteristics and survival were assessed by using univariable Cox proportional hazards models, Kaplan-Meier estimations with the Gehan-Wilcoxon test, the Mann-Whitney U test, the Kruskal-Wallis test and Spearman's correlations. A comparison of expression in tumour tissue (TT) and non-malignant mucosa tissue (MT) showed significant upregulation of CCAT1 and linc-ROR in TT (p < 0.001 and p = 0.001, respectively) and downregulation of ANRIL, MIR155HG and MALAT1 (p = 0.001, p = 0.010, p = 0.001, respectively). Linc-ROR was significantly associated with the presence of synchronous metastases (p = 0.033). For individual tissue types, lower MIR155HG expression in TT was correlated with both shorter overall survival (p = 0.008) and shorter disease-free survival (p = 0.040). In MT, expression ratios of CCAT1/ANRIL and CCAT1/MIR155HG were associated with overall survival (p = 0.005 and p = 0.006, respectively). Our results revealed that changes in expression of lncRNAs between MT and TT hold potential to be used as prognostic biomarkers in CRC patients. Moreover, the ratios of CCAT1 to ANRIL and MIR155HG in MT also exhibit potential for prognosis assessment without tumour sampling. Our results also indicate that cancer progression is associated with detrimental system-wide changes in patient tissue, which might govern patient survival even after successful elimination of tumour or cancerous cells.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a kolorektální nádory $x diagnóza $x epidemiologie $x genetika $7 D015179
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a RNA dlouhá nekódující $x genetika $7 D062085
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a upregulace $7 D015854
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hosek, Petr $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. petr.hosek@lfp.cuni.cz.
- 700 1_
- $a Kralovcova, Eva $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. Eva.Kralovcova@lfp.cuni.cz.
- 700 1_
- $a Ostasov, Pavel $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. Pavel.Ostasov@lfp.cuni.cz.
- 700 1_
- $a Liska, Vaclav $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. liskav@fnplzen.cz. Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 80, 32300 Pilsen, Czech Republic. liskav@fnplzen.cz.
- 700 1_
- $a Bruha, Jan $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. bruhaj@fnplzen.cz. Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 80, 32300 Pilsen, Czech Republic. bruhaj@fnplzen.cz.
- 700 1_
- $a Vycital, Ondrej $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. vycitalo@fnplzen.cz. Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 80, 32300 Pilsen, Czech Republic. vycitalo@fnplzen.cz.
- 700 1_
- $a Rosendorf, Jachym $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. rosendorfj@fnplzen.cz. Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 80, 32300 Pilsen, Czech Republic. rosendorfj@fnplzen.cz.
- 700 1_
- $a Opattova, Alena $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. alenaopattova@gmail.com. Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague, Czech Republic. alenaopattova@gmail.com. Institute of Biology and Medical Genetics, First Faculty of Medicine, Albertov 4, Charles University, 12800 Prague, Czech Republic. alenaopattova@gmail.com.
- 700 1_
- $a Horak, Josef $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. horajozka@seznam.cz. Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague, Czech Republic. horajozka@seznam.cz. Institute of Biology and Medical Genetics, First Faculty of Medicine, Albertov 4, Charles University, 12800 Prague, Czech Republic. horajozka@seznam.cz.
- 700 1_
- $a Kralickova, Milena $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. Milena.Kralickova@lfp.cuni.cz. Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 30166 Pilsen, Czech Republic. Milena.Kralickova@lfp.cuni.cz.
- 700 1_
- $a Vodicka, Pavel $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. pvodicka@biomed.cas.cz. Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague, Czech Republic. pvodicka@biomed.cas.cz. Institute of Biology and Medical Genetics, First Faculty of Medicine, Albertov 4, Charles University, 12800 Prague, Czech Republic. pvodicka@biomed.cas.cz.
- 700 1_
- $a Pitule, Pavel $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. pavel.pitule@lfp.cuni.cz. Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 30166 Pilsen, Czech Republic. pavel.pitule@lfp.cuni.cz.
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 19, č. 9 (2018)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30205577 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190405101240 $b ABA008
- 999 __
- $a ok $b bmc $g 1391697 $s 1050692
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 19 $c 9 $e 20180908 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- LZP __
- $a Pubmed-20190405